Sosei Group Corporation (trading as Sosei Heptares) is a research-focused biotechnology group, publicly listed in Japan (TSE: 4565) and with sites in Tokyo, London and Cambridge (UK).
Our mission is to make a significant contribution to improving the quality of life and health of people around the world. To achieve this, we will discover, design and develop the most innovative and effective medicines for patients worldwide, through our world-leading patent-protected technology and platform.
Our primary focus is the discovery, design and development of new medicines originating from its proprietary G Protein-Coupled Receptor (GPCR) targeted StaR® technology and Structure Based Drug Design (SBDD) platform capabilities. The company is advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and other rare/specialty diseases. Its leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next generation immuno-oncology approaches to treat cancer (with AstraZeneca). Our additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys.
Sosei Heptares has approximately 145 employees based at its new R&D research facility at Granta Park. The size of the company ensures a transparent linkage between all activities from early discovery through to clinical development.
As part of the newly formed Preclinical Development Group, and with the emergence of new prioritised project entering development in 2020, we are looking to strengthen the CMC team. The purpose of this role will be to progress multiple projects and the successful candidate will be supervised by the CMC Associate Director.
Key responsibilities will be:
Manage and provide scientific problem solving contributions to the small molecule drug substance CMC aspects of late stage lead optimisation, preclinical and clinical projects at Sosei Heptares, to agreed regulatory standard, timelines and budget. To include:
Be responsible for recording all batch information for drug substance for development programs.
Author, review and support CMC section of regulatory documentation:
Be an active member of Sosei Heptares groups:
Work closely with and get expert input from scientists within HTL, consultants and specialist vendors to meet the company’s objectives.
The successful candidate is expected to have:
Applicants must be able to demonstrate proof of the right to work in the United Kingdom.
We offer a competitive salary and benefits package commensurate with qualifications and experience.
Sosei Heptares is an equal opportunities employer.
Applications should include a covering letter and curriculum vitae. Please apply for this post via our on-line recruitment portal. Please attach your application in pdf format, quoting reference number 2020/1D. The closing date for applications is 29th March 2020.
Strictly no Agencies.